What is the appropriate diagnosis and treatment for suspected hantavirus infection presenting with fever, myalgia, headache, gastrointestinal symptoms, and either respiratory distress or acute kidney injury after recent rodent exposure?

Hantavirus: Diagnosis and Treatment Algorithm (prioritizing morbidity, mortality, and quality of life)

Bold recommendation: Immediately hospitalize and manage supportively in a monitored setting (ICU if hypoxemia, shock, or rising creatinine) with strict fluid-conservative resuscitation, early respiratory support (low threshold for intubation/ECMO in HCPS), and dialysis as needed; confirm with hantavirus serology (IgM/IgG) or RT-PCR and notify public health. 1, 2, 3

1) Recognize the syndrome rapidly (triage = life-saving)

• Red flags after rodent exposure (4–42 days): fever, myalgia, headache, GI symptoms plus either:

  • Respiratory distress with noncardiogenic pulmonary edema, tachycardia, hypotension → suspect HCPS/HCPS-like disease (Americas; SNV/ANDV). High mortality; rapid ICU care reduces deaths, ECMO improves survival in severe cases 1, 2, 3.
  • AKI with oliguria, thrombocytopenia, hematuria/proteinuria ± mild pulmonary findings → suspect HFRS/AKI phenotype (Old World—e.g., Puumala/Hantaan). Usually supportive care; good renal recovery in Puumala 4, 2.

• Pitfalls to avoid:

  • Do not aggressively fluid-load suspected HCPS; it worsens pulmonary edema and shock 3.
  • Don’t give empiric immunosuppression for “pulmonary-renal syndrome” until hantavirus is excluded; supportive care often suffices and avoids harm 4.

2) Immediate infection control and notification

• If ANDV risk (South America, known contact with ANDV case): isolate in private/negative-pressure room; airborne and contact precautions due to documented person-to-person transmission; notify public health urgently 1.
• For all suspected cases: standard precautions; report to health authorities (facilitates testing and outbreak control) 1, 3.

3) Diagnostic workup (don’t delay critical care)

• Labs: CBC (thrombocytopenia, hemoconcentration), BMP (BUN/Cr trend), LFTs, ABG/VBG, lactate, coagulation panel, UA (hematuria/proteinuria), type and screen.
• Imaging: CXR (interstitial/alveolar edema); consider lung ultrasound for B-lines.
• Hantavirus testing:
  • ELISA serology for IgM/IgG (diagnostic in most) 1, 2, 5.
  • RT-PCR if early in illness (first week) or for species identification (guides ANDV precautions) 2, 5.
• Differential checkpoints: exclude bacterial sepsis/pneumonia, influenza, COVID-19, leptospirosis, rickettsioses, TTP/HUS, ANCA vasculitis/anti-GBM—but prioritize supportive care while awaiting results 4, 1, 3.

4) Definitive management (supportive, organ-protective)

• Hemodynamics:
  • Use cautious, goal-directed fluids (small boluses only for overt hypoperfusion), early vasopressors for shock; avoid fluid overload to limit pulmonary edema 1, 3.
• Respiratory:
  • Oxygen to SpO2 ≥92%; early escalation to HFNC/NIV; low threshold for intubation if rapid deterioration. Consider ECMO in refractory HCPS—associated with improved survival in severe cases 1, 2, 3.
• Renal:
  • Monitor I/O, electrolytes; initiate hemodialysis for standard indications (refractory hyperkalemia, volume overload, uremia, severe acidosis, oligo-anuria with complications). Puumala AKI often recovers fully with supportive care 4, 2.
• Hematology:
  • Platelet transfusion for severe thrombocytopenia with bleeding risk; correct coagulopathy as needed 1.
• Symptom control:
  • Antipyretics (acetaminophen), analgesia; avoid NSAIDs in AKI 1.
• Antivirals:
  • No antiviral proven to reduce mortality in HCPS; ribavirin may reduce mortality in early HFRS but evidence is mixed and context-specific—do not delay critical supportive care for antivirals 2, 5.
• Disposition:
  • Admit ICU for any hypoxemia, hypotension, rising creatinine, or rapid symptom progression. Early intensivist and nephrology involvement improves outcomes 1, 2, 3.

5) Risk reduction counseling for patient and contacts (secondary prevention)

• Until ruled out, advise strict avoidance of rodent-contaminated dust; if cleaning areas with rodent activity, wet-disinfect before handling, never dry sweep/vacuum; use gloves and appropriate disinfectant (e.g., freshly prepared 1:10 bleach) per CDC guidance to reduce future morbidity and death from exposure [6–6].
• For campers/hikers/household: rodent-proofing, food in rodent-proof containers, air out closed structures 30+ minutes before entry, disinfect urine/droppings before removal; double-bag carcasses and dispose safely [6–6].

Evidence strength and nuances

• Most authoritative practical prevention guidance: CDC MMWR recommendations (guideline) for exposure mitigation and safe cleanup [6–6].
• Most recent clinical management insights with mortality focus: 2026 emergency/critical care reviews outlining diagnosis, isolation for ANDV, and organ-support strategies including ECMO and dialysis; these underpin survival in severe cases 1, 2.
• Contemporary case evidence: 2026 case report confirms AKI-predominant Puumala infection often recovers fully with supportive care, reinforcing conservative, organ-protective management to optimize QOL and avoid immunosuppression harms 4.

One-page action algorithm

• Suspect hantavirus (rodent exposure + prodrome + respiratory distress OR AKI with thrombocytopenia).
• Immediate: monitor, IV access, cautious fluids, early vasopressors if needed; oxygen → HFNC/NIV → intubation; arrange ECMO center if severe HCPS.
• Labs/imaging + send hantavirus IgM/IgG; RT-PCR if early; notify public health; airborne/contact precautions if ANDV risk.
• Start dialysis for indications; avoid NSAIDs and fluid overload.
• Reassess q1–2h in ED; admit ICU if any instability or end-organ injury. Discharge only if mild, stable, normal O2, preserved renal function, and reliable follow-up.
• Counsel on CDC rodent exposure reduction and safe cleanup to prevent recurrence [6–6,1,2,3].